A new class of drugs, Lu-PSMA-617, track down i prostate cancers resistant achieving good success and extending the life of patients.
This was declared by an international team of researchers including Professor Johann de Bono, Professor of Experimental Cancer Medicine at the Institute of Cancer Research, London, and Medical Oncologist Advisor at the Royal Marsden NHS Foundation Trust, and Professor Ken Herrmann, Director of the Nuclear Medicine Clinic at the University Hospital from Essen, Germany.
Read Also
- Covid, the study: from 3 ‘old’ drugs with high protective efficacy Jul 20, 2021
- Covid Tuscany, administered 6 physiological solutions instead of vaccine Sep 15, 2021
- Named diet, recommended by science Jul 2, 2020
- Health problems that gives the color of the language Jul 3, 2020
- Covid-19: Government awaits two opinions before deciding on unvaccinated caregivers Nov 20, 2022
- Covid, new discovery: the compatible blood group facilitates contagion Aug 20, 2021
- Military exercise of unprecedented scale in France in 2023 Nov 16, 2022